SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CVTX - CV Therapeutics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw8/22/2005 4:38:09 AM
   of 411
 
CV Therapeutics (CVTX)
9:41 AM EDT August 19, 2005
Morgan Joseph initiates BUY. Target $35. Firm notes that 3 products are expected on the market in the next 18 months, and they believe that each of the three new drugs has a competitive advantage in its respective indication. Ranexa will be the first new treatment for chronic angina in decades (Jan 27 PDUFA date, could be launched at the end of 1Q06); the expansion of the Aceon label to incorporate EUROPA data (PDUFA Sept 10), as well as additional ASCOT data to be presented at the European Society of Cardiology meeting in early Sept, should raise awareness for Aceon; firm expects positive data from the second Phase III study for Regadenoson in 4Q05.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News